Subtopic Deep Dive
Acute Pericarditis Diagnosis and Management
Research Guide
What is Acute Pericarditis Diagnosis and Management?
Acute pericarditis diagnosis and management encompasses clinical evaluation, ECG patterns, biomarker assessment, and anti-inflammatory treatments including colchicine for idiopathic and viral cases.
Guidelines recommend ECG showing widespread ST elevation for diagnosis (Adler et al., 2015, 2457 citations). Colchicine added to NSAIDs reduces recurrence rates in randomized trials (Imazio et al., 2005, 587 citations; Imazio et al., 2013, 570 citations). Over 10 key papers from 2005-2019 establish colchicine as first-line therapy.
Why It Matters
Colchicine therapy cuts recurrence by 50% in acute pericarditis, reducing hospitalizations (Imazio et al., 2013). Low-dose colchicine post-myocardial infarction lowers ischemic events by 23%, applicable to pericarditis management (Tardif et al., 2019). Anakinra treats colchicine-resistant cases, improving outcomes in corticosteroid-dependent patients (Brucato et al., 2016). Standardized protocols enhance emergency care efficiency.
Key Research Challenges
Recurrence Prediction
High recurrence rates persist despite colchicine; fever and high CRP predict poor prognosis (Imazio et al., 2007, 349 citations). Identifying at-risk patients remains difficult without validated models. Trials show 20-30% recurrence even with therapy (Imazio et al., 2013).
Colchicine Resistance
10-20% of patients fail colchicine and require alternatives like anakinra (Brucato et al., 2016, 347 citations). Corticosteroid dependence complicates management. No biomarkers reliably predict resistance upfront.
Diagnostic Differentiation
ECG changes mimic myocardial infarction; guidelines stress pericardial rub and effusion imaging (Adler et al., 2015). Effusion management risks tamponade (Imazio and Adler, 2012, 383 citations). Non-invasive biomarkers lack specificity.
Essential Papers
Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction
Jean‐Claude Tardif, Simon Kouz, David D. Waters et al. · 2019 · New England Journal of Medicine · 2.7K citations
Among patients with a recent myocardial infarction, colchicine at a dose of 0.5 mg daily led to a significantly lower risk of ischemic cardiovascular events than placebo. (Funded by the Government ...
2015 ESC Guidelines for the diagnosis and management of pericardial diseases
Yehuda Adler, Philippe Charron, Massimo Imazio et al. · 2015 · European Heart Journal · 2.5K citations
The ESC Guidelines represent the views of the ESC and were produced after careful consideration of the scientific and medical knowledge and the evidence available at the time of their publication. ...
Colchicine in Addition to Conventional Therapy for Acute Pericarditis
Massimo Imazio, Marco Bobbio, Enrico Cecchi et al. · 2005 · Circulation · 587 citations
Background— Colchicine is effective and safe for the treatment and prevention of recurrent pericarditis and might ultimately serve as the initial mode of treatment, especially in idiopathic cases. ...
A Randomized Trial of Colchicine for Acute Pericarditis
Massimo Imazio, Antonio Brucato, Roberto Cemin et al. · 2013 · New England Journal of Medicine · 570 citations
In patients with acute pericarditis, colchicine, when added to conventional antiinflammatory therapy, significantly reduced the rate of incessant or recurrent pericarditis. (Funded by former Aziend...
Colchicine as First-Choice Therapy for Recurrent Pericarditis
Massimo Imazio, Marco Bobbio, Enrico Cecchi et al. · 2005 · Archives of Internal Medicine · 408 citations
Colchicine therapy led to a clinically important and statistically significant benefit over conventional treatment, decreasing the recurrence rate in patients with a first episode of recurrent peri...
Management of pericardial effusion
Massimo Imazio, Yehuda Adler · 2012 · European Heart Journal · 383 citations
Pericardial effusion is a common finding in clinical practice either as incidental finding or manifestation of a systemic or cardiac disease. The spectrum of pericardial effusions ranges from mild ...
Pericardial Disease
William C. Little, Gregory L. Freeman · 2006 · Circulation · 351 citations
I n contrast to coronary artery disease, heart failure, valvular disease, and other topics in the field of cardiology, there are few data from randomized trials to guide physicians in the managemen...
Reading Guide
Foundational Papers
Start with Imazio et al. (2005, 587 citations) for colchicine RCT in acute cases and Adler et al. (2015, 2457 citations) for ESC diagnostic criteria, as they anchor therapy standards.
Recent Advances
Study Tardif et al. (2019, 2727 citations) for low-dose colchicine safety and Brucato et al. (2016, 347 citations) for anakinra in resistant pericarditis.
Core Methods
ECG interpretation, CRP biomarkers, colchicine dosing (0.5mg daily), echocardiography for effusion; RCTs dominate evidence (Imazio series).
How PapersFlow Helps You Research Acute Pericarditis Diagnosis and Management
Discover & Search
Research Agent uses searchPapers and citationGraph on 'colchicine pericarditis' to map 587-citation Imazio et al. (2005) as hub, linking to Tardif et al. (2019) and Adler et al. (2015); exaSearch uncovers 50+ related trials.
Analyze & Verify
Analysis Agent applies readPaperContent to extract recurrence rates from Imazio et al. (2013), verifies with CoVe against Adler guidelines, and runs PythonAnalysis on GRADE scoring for colchicine evidence (high-quality RCTs). Statistical verification computes risk reductions from trial data.
Synthesize & Write
Synthesis Agent detects gaps in colchicine resistance therapies post-Bruciato et al. (2016); Writing Agent uses latexEditText for guidelines summary, latexSyncCitations for Adler et al. (2015), and exportMermaid for ECG-to-therapy flowcharts.
Use Cases
"Meta-analyze colchicine recurrence rates from RCTs in acute pericarditis"
Research Agent → searchPapers → Analysis Agent → runPythonAnalysis (pandas meta-analysis of Imazio 2005/2013 data) → GRADE report with 95% CI risk reductions.
"Write LaTeX review on ESC pericarditis guidelines vs recent trials"
Synthesis Agent → gap detection → Writing Agent → latexEditText + latexSyncCitations (Adler 2015) + latexCompile → PDF with Tardif 2019 integration.
"Find analysis code for pericarditis biomarkers from papers"
Research Agent → paperExtractUrls → Code Discovery → paperFindGithubRepo → githubRepoInspect → runnable Python for CRP prognosis modeling.
Automated Workflows
Deep Research workflow scans 50+ papers via citationGraph from Imazio et al. (2005), generates structured report on colchicine efficacy with GRADE scores. DeepScan applies 7-step CoVe to verify recurrence predictors from Imazio et al. (2007). Theorizer builds therapy escalation models from Adler guidelines and Brucato anakinra data.
Frequently Asked Questions
What defines acute pericarditis diagnosis?
Chest pain, pericardial rub, and ECG with PR depression/ST elevation; supported by effusion on echo (Adler et al., 2015).
What are standard management methods?
NSAIDs plus colchicine for 3 months reduces recurrence by 50% (Imazio et al., 2013, 570 citations).
Which papers established colchicine efficacy?
Imazio et al. (2005, 587 citations) and Imazio et al. (2013, 570 citations) via RCTs showing safety and recurrence prevention.
What are open problems in management?
Colchicine resistance in 10-20% cases needs biomarkers; anakinra helps but lacks large trials (Brucato et al., 2016).
Research Pericarditis and Cardiac Tamponade with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Acute Pericarditis Diagnosis and Management with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers